Related Experiment Video
Updated: Jun 25, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
p53 Deficiency leads to compensatory up-regulation of p16INK4a
Wai Fook Leong1, Jenny Fung Ling Chau, Baojie Li
1Cancer and Developmental Biology Division, The Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research, Singapore.
Abstract:
p53-p21-cyclin-dependent kinase and p16(INK4a)-cyclin-dependent kinase pathways have parallel functions in preventing tumorigenesis. In cancer patients, tumor suppressor p53 is frequently inactivated through mutations, whereas p16(INK4a) is silenced through promoter methylation. However, the interaction between these two pathways is less well understood. Here, we report that p53 controls p16(INK4a) expression in a unique way. p53 deficiency led to up-regulation of p16(INK4a) in primary mouse embryonic fibroblasts, osteoblasts, and various mouse organs, and an increase in the p16(INK4a) promoter activity, without affecting the half-life of p16(INK4a). Reconstitution of p53, but not mutant p53, restored the proper expression of p16(INK4a). These results indicate that p53 is necessary in repressing p16(INK4a) expression. However, up-regulation of p53 in response to genotoxic stress or nutlin-3 treatment did not down-regulate p16(INK4a). p53 did not repress the p16(INK4a) promoter activity either. These findings suggest that p53 has a necessary but not sufficient role in repressing p16(INK4a) expression. p16(INK4a) elevation in p53(-/-) cells is, at least partially, mediated by Ets1, a known positive regulator of p16(INK4a), as p53 deficiency up-regulated Ets1 through protein stabilization and knockdown of Ets1 down-regulated p16(INK4a) expression in p53(-/-) mouse embryonic fibroblasts. These studies uncover a compensatory mechanism for the loss of p53 and provide a basis for targeting both p53 and p16(INK4a) in cancer therapy.
Insights
The tumor suppressor p53 normally represses p16(INK4a) expression. Loss of p53 function leads to increased p16(INK4a) via Ets1, suggesting a compensatory mechanism in cancer therapy.
Area of Science:
- Molecular Biology
- Cancer Biology
- Cell Cycle Regulation
Background:
- The p53-p21-cyclin-dependent kinase and p16(INK4a)-cyclin-dependent kinase pathways are crucial for preventing tumor formation.
- Tumor suppressor p53 is often inactivated in cancer, while p16(INK4a) is frequently silenced by promoter methylation.
- The interplay between the p53 and p16(INK4a) pathways in tumorigenesis remains incompletely understood.
Purpose of the Study:
- To elucidate the regulatory relationship between p53 and p16(INK4a) expression.
- To investigate the mechanisms underlying p16(INK4a) dysregulation in the absence of functional p53.
- To identify potential therapeutic targets based on the interaction between these pathways.
Main Methods:
- Analysis of p16(INK4a) expression and promoter activity in p53-deficient and wild-type mouse embryonic fibroblasts, osteoblasts, and organs.
- Assessment of p16(INK4a) regulation upon p53 reconstitution and in response to genotoxic stress or nutlin-3.
- Investigation of the role of Ets1 in mediating p16(INK4a) up-regulation in p53-deficient cells using knockdown experiments.
Main Results:
- p53 deficiency led to increased p16(INK4a) expression and promoter activity in various cell types and organs.
- Functional p53, but not mutant p53, restored normal p16(INK4a) levels, indicating p53's role in repressing p16(INK4a).
- p53's repression of p16(INK4a) was found to be necessary but not sufficient, with Ets1 identified as a key mediator of p16(INK4a) up-regulation in p53-deficient cells.
Conclusions:
- p53 plays a critical role in suppressing p16(INK4a) expression, and its loss leads to compensatory up-regulation of p16(INK4a).
- The transcription factor Ets1 mediates the elevated p16(INK4a) levels observed in p53-deficient cells.
- These findings reveal a compensatory mechanism that could be exploited for combined targeting of p53 and p16(INK4a) in cancer therapy.
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Negative Regulator Molecules
Inhibition of Cdk Activity
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
